Cytogenetic Studies For Previously Untreated AML, ALL or MDS Patients (Companion To CALGB Treatment Studies For Previously Untreated AML, ALL Or MDS Patients)
| City: |
|
Asheville |
| State: |
|
North Carolina |
| Zip Code: |
|
28801 |
| Conditions: |
|
Leukemia - Multiple Myeloma and Plasma Cell Neoplasm - Myelodysplastic Syndromes - Myelodysplastic/Myeloproliferative Neoplasms |
| Purpose: |
|
RATIONALE: Cytogenetic tests may help predict how cancer will respond to treatment and allow
doctors to plan more effective therapy.
PURPOSE: This diagnostic trial is studying genetic differences in patients with treated and
untreated acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes,
or multiple myeloma.
|
| Study Summary: |
|
OBJECTIVES:
- Determine the incidence of chromosomal abnormalities in patients with acute myeloid
leukemia, acute lymphoblastic leukemia, myelodysplastic syndromes, or multiple myeloma.
- Correlate specific chromosomal abnormalities with clinical and laboratory parameters in
these patients.
- Correlate specific karyotype groups with treatment response rates, response duration,
survival, and cure in patients treated with various induction and post-induction
regimens.
- Correlate specific karyotype groups with multidrug resistance data in these patients.
- Identify new chromosome abnormalities important in leukemogenesis.
- Correlate specific karyotype groups with epidemiological data (toxic exposure and
family history) in these patients.
- Determine karyotype changes at relapse and the influence of the type of change (or no
change) in karyotype at relapse in subsequent clinical courses in these patients.
- Correlate specific karyotype groups with selected molecular abnormalities as studied in
CALGB leukemia protocols.
OUTLINE: This is a multicenter study.
Patients undergo collection of bone marrow and blood specimens for cytogenetic analysis at
diagnosis, complete remission, and relapse. Specimens are karyotyped and examined for
chromosomal abnormalities.
PROJECTED ACCRUAL: Approximately 6,400 patients will be accrued for this study.
|
| Criteria: |
|
DISEASE CHARACTERISTICS:
- Must enroll (within 1 month of registration on this study) on a CALGB treatment study
for previously untreated acute myeloid leukemia, acute lymphoblastic leukemia, or
myelodysplastic syndromes
- Patients enrolled on CLB-100001 (previously treated or untreated multiple myeloma)
must enroll on this study
- Simultaneous registration on CLB-9665 (within the continental United States)
PATIENT CHARACTERISTICS:
Age
- 15 and over
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- Not specified
Renal
- Not specified
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
- Not specified
Endocrine therapy
- Not specified
Radiotherapy
- Not specified
Surgery
- Not specified
|
| NCT ID: |
|
NCT00048958 |
| Primary Contact: |
|
Study Chair
Clara D. Bloomfield, MD
Arthur G. James Cancer Hospital & Richard J. Solove Research Institute
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Asheville, North Carolina 28801
United States
Clinical Trials Office - Mission Hospitals - Memorial Campus
Phone: 828-213-4150
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 25, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|